Patrick Miles Sells 43,459 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Patrick Miles sold 43,459 shares of the company’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $11.95, for a total transaction of $519,335.05. Following the transaction, the chief executive officer now owns 6,065,772 shares of the company’s stock, valued at $72,485,975.40. This represents a 0.71 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Patrick Miles also recently made the following trade(s):

• On Wednesday, January 29th, Patrick Miles sold 50,000 shares of Alphatec stock. The stock was sold at an average price of $12.03, for a total value of $601,500.00.
• On Tuesday, January 21st, Patrick Miles sold 6,687 shares of Alphatec stock. The shares were sold at an average price of $12.00, for a total value of $80,244.00.

Alphatec Price Performance

Shares of NASDAQ ATEC traded down $0.06 during midday trading on Friday, reaching $11.36. The company’s stock had a trading volume of 998,281 shares, compared to its average volume of 1,776,835. Alphatec Holdings, Inc. has a one year low of $4.88 and a one year high of $17.34. The company has a market cap of $1.61 billion, a price-to-earnings ratio of -8.88 and a beta of 1.43. The company has a 50 day moving average price of $10.26 and a 200 day moving average price of $8.13. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21.

Institutional Trading of Alphatec

Hedge funds have recently modified their holdings of the business. AlphaQuest LLC purchased a new position in shares of Alphatec during the fourth quarter valued at $80,000. PNC Financial Services Group Inc. grew its stake in Alphatec by 0.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 312,954 shares of the medical technology company’s stock valued at $2,873,000 after acquiring an additional 1,120 shares in the last quarter. Mesirow Financial Investment Management Inc. increased its holdings in shares of Alphatec by 93.8% in the 4th quarter. Mesirow Financial Investment Management Inc. now owns 44,508 shares of the medical technology company’s stock valued at $409,000 after purchasing an additional 21,546 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Alphatec in the fourth quarter worth approximately $358,000. Finally, M&T Bank Corp acquired a new stake in shares of Alphatec during the fourth quarter worth approximately $170,000. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ATEC. Barclays increased their price target on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 22nd. Needham & Company LLC boosted their price target on shares of Alphatec from $13.00 to $16.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Alphatec in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $17.56.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.